Pyxis Oncology, Inc. (PYXS)
US — Healthcare Sector
Automate Your Wheel Strategy on PYXS
With Tiblio's Option Bot, you can configure your own wheel strategy including PYXS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PYXS
- Rev/Share 0.0557
- Book/Share 1.6889
- PB 0.7224
- Debt/Equity 0.1924
- CurrentRatio 7.7527
- ROIC -0.8491
- MktCap 75576153.0
- FreeCF/Share -0.9736
- PFCF -1.2716
- PE -0.7821
- Debt/Assets 0.146
- DivYield 0
- ROE -0.696
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
PYXS
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: April 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders
Read More
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
PYXS,
RLAY,
VSTM
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
Read More
About Pyxis Oncology, Inc. (PYXS)
- IPO Date 2021-10-08
- Website https://www.pyxisoncology.com
- Industry Biotechnology
- CEO Dr. Lara S. Sullivan M.D., MBA
- Employees 44
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.